EGFR and lung adenocarcinoma: Another case report showed that a patient with recurrent IV postoperative lung adenocarcinoma progressed again with multiple lines of treatment, including gefitinib, radiotherapy, and immunotherapy, and genetic testing was performed suggesting EGFR L858R and L747V mutations, and a 1-year PFS was obtained after treatment with afatinib [27].